ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
… Trial enrollment continuing for three clinical stage RNA therapies in development for inherited retinal diseases, … (SAB) with leaders in inherited retinal disease and RNAtherapy. The SAB members are: James Shannon, MD, Chair of the …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … 1b/2 trial results of the intravitreal sepofarsen RNAtherapy in LCA10 (encore presentations) Full-field stimulus …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st
